Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months OldDuration of Treatment To-Date Ranges from 3 Weeks to 15 MonthsNo Treatment Related Adverse Events Reported for All Six Patients Additional Pediatric Patients Enrolling in Program in June and September Quoin Plans a Comprehensiv